The daily use of skin moisturising creams or emollients along with avoidance of specific and unspecific irritants play a crucial role in the management of atopic dermatitis (AD). However, the repeated application of an emollient during the day interferes with the usual daily activities. An emollient in a stick format might facilitate the use and can be applied whenever the skin feels dry during the day. A recent study assessed the use of a stick in addition to an emollient balm and its influence on AD symptoms in 69 patients with mild-to-moderate AD. The stick contained the anti-inflammatory agent madecassoside, shea butter to support the barrier function, and zinc gluconate for its anti-bacterial properties.
All patients had a SCORing Atopic Dermatitis (SCORAD) score ≥2 at the screening visit. They were advised to apply an emollient in the evening and the stick on lesional skin during the day as needed. Changes in AD symptoms, pruritus intensity, and influence on quality of life were assessed after 14 days and 28 days and compared with day 0.
The use of this skin regimen lead to a reduction of the SCORAD by -32.4% at day 14 and -47.4% by day 28 (P≤0.001 compared with day 0). Concomitantly, the Eczema Area and Severity Index (EASI) dropped by -44.5% at day 14 and -62.3% at day 28 (P≤0.001 compared with day 0). The improvement of the skin lesions was also noticed in the Investigator’s Global Assessment (IGA): severity of the disease decreased on average by 27.1% at day 14 and 38.5% at day 28 (P≤0.001 compared with day 0). Itch was reduced by 36.6% at day 14 and by 55.5% at day 28 (see Figure). The quality of life assessed in the Dermatology Life Quality Index improved significantly at both time points compared with day 0 (P≤0.001).
Figure: A significant improvement of pruritus with a -36.6% and -55.4% reduction at day 14 and 28 [1]
* P≤0.001 versus day 0.
The authors conclude that the combination of an emollient balm and stick allowed AD patients to treat their atopic lesions more often and more easily during the day. This simple addition to the usual skin care regimen translated into an improvement of all objective and subjective signs and skin symptoms. In addition, itch was lowered and quality of life increased.
For more articles on Type 2 Inflammation, see our independent webportal inflammation-type2.org.
- Moyal D. P14186, AAD Virtual Meeting Experience, 12-14 June 2020.
Posted on
Previous Article
« EAU20 Virtual Next Article
Omalizumab for cancer-induced dermatoses »
« EAU20 Virtual Next Article
Omalizumab for cancer-induced dermatoses »
Table of Contents: AAD 2020
Featured articles
Late-Breaking Abstracts
IL-17A and IL-17F blockade remarkably effective in psoriasis
Good response and pruritus reduction in AD with novel selective JAK1 inhibitor
Novel IL-23 blocker risankizumab highly effective and tolerable in psoriasis
Tape stripping – a painless way to distinguish AD and psoriasis?
IL-4/IL-13 blocker dupilumab effective in children with severe AD
Pembrolizumab leads to higher toxicity risk in obese melanoma patients
Can gene expression help to pick the right biologic to treat psoriasis in cancer patients?
Omalizumab for cancer-induced dermatoses
Psoriasis – What Is Hot?
Psoriasis therapy for children and pregnancies
Biologic psoriasis treatment to lower cardiovascular risk?
Systemic Therapies for Dermatologists
How to manage cutaneous side effects of immunotherapy
Cannabinoids: a future role in dermatology?
Hidradenitis Suppurativa/Acne Inversa
Biologics in HS – a growing armamentarium
Pearls of the Posters
Selective IL-23 blocker safe in elderly psoriasis patients
Spironolactone safe for androgenetic alopecia in cancer survivors
Baricitinib beneficial in head and neck AD
ECLIPSE trial: skin clearance independent of PsA status at baseline
Related Articles
August 6, 2020
Biologics in HS – a growing armamentarium
August 6, 2020
Psoriasis therapy for children and pregnancies
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com